Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib, or belumosudil in murine sclerodermatous GVHD

Hong X, Xiao Y, Xu L, Shen L, Neelagar R, Devakumar V, Trinh-Minh T, Liang M, Rigau AR, Zhang Y, Li YN, Dees C, Györfi AH, Wolff D, Herr W, Schett G, Distler JH, Matei AE (2025)

Publication Type: Journal article

Publication year: 2025

Journal

Blood Advances American Society of Hematology

Book Volume: 9

Pages Range: 1261-1266

Journal Issue: 6

DOI: 10.1182/bloodadvances.2024014387

Authors with CRIS profile

Lichong Shen Professur für Molekulare Mechanismen der Organfibrose Aleix Rius Rigau Department of Medicine 3 – Rheumatology and Immunology Clara Dees Department of Medicine 3 – Rheumatology and Immunology Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

Universitätsklinikum Düsseldorf DE Germany (DE) Universitätsklinikum Regensburg DE Germany (DE)

How to cite

APA:

Hong, X., Xiao, Y., Xu, L., Shen, L., Neelagar, R., Devakumar, V.,... Matei, A.E. (2025). Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib, or belumosudil in murine sclerodermatous GVHD. Blood Advances, 9(6), 1261-1266. https://doi.org/10.1182/bloodadvances.2024014387

MLA:

Hong, Xuezhi, et al. "Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib, or belumosudil in murine sclerodermatous GVHD." Blood Advances 9.6 (2025): 1261-1266.

BibTeX: Download